Altimmune, Inc. — Director's Dealing 2022

Jun 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2022-06-15

Reporting Person: Drutz David (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-15	Common Stock, par value $0.0001	P	1000	$8.00	Acquired	20012	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001	333	Indirect

Footnotes

F1: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.